Literature DB >> 18427556

Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice.

Maria van der Sluis1, Janneke Bouma, Audrey Vincent, Anna Velcich, Kermit L Carraway, Hans A Büller, Alexandra W C Einerhand, Johannes B van Goudoever, Isabelle Van Seuningen, Ingrid B Renes.   

Abstract

Expression of the mucin MUC2, the structural component of the colonic mucus layer, is lowered in ulcerative colitis. Furthermore, interleukin (IL)-10 knockout (IL-10-/-) mice develop colitis and have reduced Muc2 levels. Our aim was to obtain insight into the role of Muc2 and IL-10 in epithelial protection. Muc2-IL-10 double-knockout (Muc2/IL-10(DKO)) mice were characterized and compared to Muc2 knockout (Muc2-/-), IL-10-/- and wild-type (WT) mice. Clinical symptoms, intestinal morphology and differences in epithelial-specific protein levels were analyzed. In addition, levels of the pro-inflammatory cytokines in colonic tissue and serum were determined. IL-10-/- mice were indistinguishable from WT mice throughout this experiment and showed no clinical or histological signs of colitis. Muc2/IL-10(DKO) and Muc2-/- mice showed significant growth retardation and clinical signs of colitis at 4 and 5 weeks, respectively. Muc2/IL-10(DKO) mice had a high mortality rate (50% survival/5 weeks) compared to the other types of mice (100% survival). Microscopic analysis of the colon of Muc2/IL-10(DKO) mice showed mucosal thickening, increased proliferation, superficial erosions and a diminished Muc4 expression. Furthermore, pro-inflammatory cytokines were significantly upregulated, both in tissue (mRNA) and systemically in Muc2/IL-10(DKO) mice. In conclusion, Muc2/IL-10(DKO) mice develop colitis, which is more severe in every aspect compared to Muc2-/- and IL-10-/- mice. These data indicate that (i) in case of Muc2 deficiency, the anti-inflammatory cytokine IL-10 can control epithelial damage, though to a limited extent and (ii) the mucus layer is most likely a key factor determining colitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427556     DOI: 10.1038/labinvest.2008.28

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  16 in total

Review 1.  Crohn disease: a current perspective on genetics, autophagy and immunity.

Authors:  Thaddeus S Stappenbeck; John D Rioux; Atsushi Mizoguchi; Tatsuya Saitoh; Alan Huett; Arlette Darfeuille-Michaud; Tom Wileman; Noboru Mizushima; Simon Carding; Shizuo Akira; Miles Parkes; Ramnik J Xavier
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

Review 2.  New developments in goblet cell mucus secretion and function.

Authors:  G M H Birchenough; M E V Johansson; J K Gustafsson; J H Bergström; G C Hansson
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

Review 3.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 4.  Protective and pro-inflammatory roles of intestinal bacteria.

Authors:  Cynthia Reinoso Webb; Iurii Koboziev; Kathryn L Furr; Matthew B Grisham
Journal:  Pathophysiology       Date:  2016-02-17

5.  Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease.

Authors:  Dermot P B McGovern; Michelle R Jones; Kent D Taylor; Kristin Marciante; Xiaofei Yan; Marla Dubinsky; Andy Ippoliti; Eric Vasiliauskas; Dror Berel; Carrie Derkowski; Deb Dutridge; Phil Fleshner; David Q Shih; Gil Melmed; Emebet Mengesha; Lily King; Sheila Pressman; Talin Haritunians; Xiuqing Guo; Stephan R Targan; Jerome I Rotter
Journal:  Hum Mol Genet       Date:  2010-06-22       Impact factor: 6.150

6.  Muc-2-deficient mice display a sex-specific, COX-2-related impairment of gastric mucosal repair.

Authors:  John L Wallace; Linda Vong; Poonam Dharmani; Vikas Srivastava; Kris Chadee
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

7.  Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases.

Authors:  Edmond Y Huang; Takuya Inoue; Vanessa A Leone; Sushila Dalal; Ketrija Touw; Yunwei Wang; Mark W Musch; Betty Theriault; Kazuhide Higuchi; Sharon Donovan; Jack Gilbert; Eugene B Chang
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

8.  Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis.

Authors:  M Wlodarska; B Willing; K M Keeney; A Menendez; K S Bergstrom; N Gill; S L Russell; B A Vallance; B B Finlay
Journal:  Infect Immun       Date:  2011-02-14       Impact factor: 3.441

Review 9.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

10.  Mucin pre-cultivated Lactobacillus reuteri E shows enhanced adhesion and increases mucin expression in HT-29 cells.

Authors:  Boris Dudík; Hana Kiňová Sepová; František Bilka; Ľudmila Pašková; Andrea Bilková
Journal:  Antonie Van Leeuwenhoek       Date:  2020-05-14       Impact factor: 2.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.